Dose-to-target of etanercept treatment in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
- Conditions
- Etanercept, dose-to-target, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, personalized medicine
- Registration Number
- NL-OMON24861
- Lead Sponsor
- Jan van Breemen Research Institute | Reade
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 250
Inclusion Criteria
1. Diagnosis: RA (according to the American College of Rheumatology 1987 criteria), or PsA (according to the Classification of Psoriatic Arthritis criteria) or AS (according to the 1984 New York Criteria);
2. Treatment with etanercept 50 mg SC weekly (or 25 mg SC twice weekly) for at least 6 subsequent months;
Exclusion Criteria
Planned reasons for treatment discontinuation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the proportion of patients with RA, AS or PsA maintaining Minimal Disease Activity after dose interval prolongation of etanercept.
- Secondary Outcome Measures
Name Time Method 1. To study the cost-effectiveness of tapering down etanercept treatment;<br /><br>2. To investigate whether the lowest effective etanercept dose will reduce the risk of adverse events;<br /><br>3. To study the predictive value of serum etanercept trough levels and other patient related factors for successful down titration.